💊
Hympavzi
marstacimab
Hemofilie A;Hemofilie B
✅ Autorizat
✅
Nu există alerte active
Acest medicament nu are penurii în curs, scrisori de siguranță sau retrageri de pe piață.
La ce se utilizează
Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with: Haemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors who have severe disease (FVIII < 1%) with factor VIII inhibitors Haemophilia B (congenital factor IX deficiency) without factor IX inhibitors who have severe disease (FIX < 1%) with factor IX inhibitors.
⚠️ Siguranță a pacientului
No
Pagina oficială EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/hympavzi